File downloaded on 2026-06-17
Source URL: https://medicines.health.europa.eu/veterinary/en/600000085713

BUSCOPAN COMPOSITUM ad us. vet. 4 mg/ml + 500 mg/ml, oplossing voor injectie voor paarden, kalveren en honden

Authorised

- Metamizole sodium
- Hyoscine butylbromide

Product identification

Medicine name:
BUSCOPAN COMPOSITUM ad us. vet. 4 mg/ml + 500 mg/ml, oplossing voor injectie voor paarden, kalveren en honden

Active substance:
Metamizole sodium
Hyoscine butylbromide

Target species:
Horse
Dog
Cattle
Cattle (calf)

Route of administration:
Intravenous use
Subcutaneous use

Product details

Active substance and strength:
Metamizole sodium
500.00 milligram(s) / 1.00 millilitre(s)

Hyoscine butylbromide
4.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Solution for injection

Withdrawal period by route of administration:
Intravenous use:

- **Horse**
  - Meat and offal. 12 day
  - Milk. no withdrawal period

Not to be used in animals producing milk for human consumption

- **Cattle**
  - Milk. no withdrawal period

Not to be used in animals producing milk for human consumption

- **Cattle (calf)**
  - Meat and offal. 15 day

Subcutaneous use:

- **Horse**
  - Meat and offal. 12 day

- Milk. no withdrawal period

Not to be used in animals producing milk for human consumption

- **Cattle**
  - Milk. no withdrawal period

Not to be used in animals producing milk for human consumption

- **Cattle (calf)**
  - Meat and offal. 15 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QA03BB01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Belgium

Available in:
Belgium

Package description:
Buscopan Compositum ad us. vet 1 Vial of 100 ml with Solution for injection

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Boehringer Ingelheim Vetmedica GmbH

Marketing authorisation date:
31/12/1991

Manufacturing sites for batch release:
Labiana Life Sciences S.A.

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V158261

Date of authorisation status change:
16/06/2022

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.